BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BRM - US1101221083 - Common Stock
42.135 EUR
0 (0%)
Overall BRM gets a fundamental rating of 6 out of 10. We evaluated BRM against 55 industry peers in the Pharmaceuticals industry. BRM has only an average score on both its financial health and profitability. A decent growth rate in combination with a cheap valuation! Better keep an eye on BRM. BRM also has an excellent dividend rating. This makes BRM very considerable for value and dividend investing!
1. Profitability
1.1 Basic Checks
BRM had positive earnings in the past year.
BRM had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BRM reported negative net income in multiple years.
In the past 5 years BRM always reported a positive cash flow from operatings.
1.2 Ratios
With a Return On Assets value of 6.23%, BRM perfoms like the industry average, outperforming 56.36% of the companies in the same industry.
BRM's Return On Equity of 32.55% is fine compared to the rest of the industry. BRM outperforms 80.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 16.42%, BRM is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
BRM had an Average Return On Invested Capital over the past 3 years of 10.96%. This is below the industry average of 14.90%.
The 3 year average ROIC (10.96%) for BRM is below the current ROIC(16.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROIC | 16.42% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
BRM has a Profit Margin (12.57%) which is in line with its industry peers.
Looking at the Operating Margin, with a value of 33.51%, BRM belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
BRM's Operating Margin has declined in the last couple of years.
BRM's Gross Margin of 73.15% is in line compared to the rest of the industry. BRM outperforms 58.18% of its industry peers.
In the last couple of years the Gross Margin of BRM has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
BRM has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
BRM has less shares outstanding than it did 1 year ago.
BRM has less shares outstanding than it did 5 years ago.
BRM has a worse debt/assets ratio than last year.
2.2 Solvency
BRM has an Altman-Z score of 2.14. This is not the best score and indicates that BRM is in the grey zone with still only limited risk for bankruptcy at the moment.
BRM has a Altman-Z score (2.14) which is in line with its industry peers.
BRM has a debt to FCF ratio of 3.20. This is a good value and a sign of high solvency as BRM would need 3.20 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.20, BRM is in the better half of the industry, outperforming 61.82% of the companies in the same industry.
BRM has a Debt/Equity ratio of 2.41. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of BRM (2.41) is worse than 78.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Altman-Z | 2.14 |
ROIC/WACC2.06
WACC7.98%
2.3 Liquidity
A Current Ratio of 1.27 indicates that BRM should not have too much problems paying its short term obligations.
BRM's Current ratio of 1.27 is on the low side compared to the rest of the industry. BRM is outperformed by 61.82% of its industry peers.
A Quick Ratio of 1.17 indicates that BRM should not have too much problems paying its short term obligations.
BRM has a better Quick ratio (1.17) than 67.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 460.68% over the past year.
The earnings per share for BRM have been decreasing by -24.57% on average. This is quite bad
The Revenue has been growing slightly by 1.26% in the past year.
Measured over the past years, BRM shows a quite strong growth in Revenue. The Revenue has been growing by 13.06% on average per year.
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
3.2 Future
The Earnings Per Share is expected to grow by 35.26% on average over the next years. This is a very strong growth
Based on estimates for the next years, BRM will show a decrease in Revenue. The Revenue will decrease by -5.17% on average per year.
EPS Next Y472.54%
EPS Next 2Y131.12%
EPS Next 3Y73.23%
EPS Next 5Y35.26%
Revenue Next Year-0.35%
Revenue Next 2Y-4.29%
Revenue Next 3Y-3.28%
Revenue Next 5Y-5.17%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
BRM is valuated cheaply with a Price/Earnings ratio of 7.42.
92.73% of the companies in the same industry are more expensive than BRM, based on the Price/Earnings ratio.
BRM is valuated cheaply when we compare the Price/Earnings ratio to 25.98, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 7.99, the valuation of BRM can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BRM indicates a rather cheap valuation: BRM is cheaper than 89.09% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 35.79. BRM is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.42 | ||
| Fwd PE | 7.99 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BRM is valued cheaply inside the industry as 90.91% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, BRM is valued cheaper than 98.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.47 | ||
| EV/EBITDA | 6.21 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as BRM's earnings are expected to grow with 73.23% in the coming years.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y131.12%
EPS Next 3Y73.23%
5. Dividend
5.1 Amount
BRM has a Yearly Dividend Yield of 5.40%, which is a nice return.
Compared to an average industry Dividend Yield of 3.00, BRM pays a better dividend. On top of this BRM pays more dividend than 90.91% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.41, BRM pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.4% |
5.2 History
The dividend of BRM is nicely growing with an annual growth rate of 11.67%!
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
82.81% of the earnings are spent on dividend by BRM. This is not a sustainable payout ratio.
BRM's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP82.81%
EPS Next 2Y131.12%
EPS Next 3Y73.23%
FRA:BRM (11/25/2025, 4:42:00 PM)
42.135
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.84%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap85.76B
Revenue(TTM)48.03B
Net Income(TTM)6.04B
Analysts67.88
Price Target45.93 (9.01%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.4% |
Yearly Dividend2.1
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)3.83%
PT rev (3m)1.63%
EPS NQ rev (1m)4.98%
EPS NQ rev (3m)4.45%
EPS NY rev (1m)0.81%
EPS NY rev (3m)-0.81%
Revenue NQ rev (1m)2.05%
Revenue NQ rev (3m)2.21%
Revenue NY rev (1m)0.74%
Revenue NY rev (3m)0.93%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.42 | ||
| Fwd PE | 7.99 | ||
| P/S | 2.06 | ||
| P/FCF | 6.47 | ||
| P/OCF | 5.96 | ||
| P/B | 5.34 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.21 |
EPS(TTM)5.68
EY13.48%
EPS(NY)5.27
Fwd EY12.52%
FCF(TTM)6.51
FCFY15.46%
OCF(TTM)7.07
OCFY16.79%
SpS20.44
BVpS7.9
TBVpS-10.07
PEG (NY)0.02
PEG (5Y)N/A
Graham Number31.77
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROCE | 23.41% | ||
| ROIC | 16.42% | ||
| ROICexc | 21.58% | ||
| ROICexgc | 109.99% | ||
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% | ||
| FCFM | 31.86% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.99%
ROICexgc(3y)70.36%
ROICexgc(5y)72.03%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score6
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Debt/EBITDA | 2.13 | ||
| Cap/Depr | 26.84% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 79.11% | ||
| Profit Quality | 253.39% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.14 |
F-Score6
WACC7.98%
ROIC/WACC2.06
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
EPS Next Y472.54%
EPS Next 2Y131.12%
EPS Next 3Y73.23%
EPS Next 5Y35.26%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
Revenue Next Year-0.35%
Revenue Next 2Y-4.29%
Revenue Next 3Y-3.28%
Revenue Next 5Y-5.17%
EBIT growth 1Y44.7%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year263.82%
EBIT Next 3Y49.42%
EBIT Next 5Y23.49%
FCF growth 1Y30.91%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y28.71%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%
BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ
What is the fundamental rating for BRM stock?
ChartMill assigns a fundamental rating of 6 / 10 to BRM.DE.
What is the valuation status for BRM stock?
ChartMill assigns a valuation rating of 9 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.
How profitable is BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 5 / 10.
How financially healthy is BRISTOL-MYERS SQUIBB CO?
The financial health rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 5 / 10.
What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to grow by 472.54% in the next year.